The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Levoleucovorin (Brand name: Fusilev™)
- Manufactured by
Spectrum Pharmaceuticals, Inc.
FDA-approved indication: Levoleucovorin rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Levoleucovorin is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid
National Library of Medicine Drug Information Portal